Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Soligenix, Inc. (SNGX)

0.56   -0.015 (-2.61%) 12-02 15:59
Open: 0.55 Pre. Close: 0.575
High: 0.5816 Low: 0.55
Volume: 98,469 Market Cap: 24(M)

Technical analysis

as of: 2022-12-02 4:26:14 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.77     One year: 0.85
Support: Support1: 0.55    Support2: 0.45
Resistance: Resistance1: 0.66    Resistance2: 0.73
Pivot: 0.61
Moving Average: MA(5): 0.56     MA(20): 0.62
MA(100): 0.69     MA(250): 0.65
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 8.5     %D(3): 9
RSI: RSI(14): 36.5
52-week: High: 1  Low: 0.37
Average Vol(K): 3-Month: 76 (K)  10-Days: 50 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SNGX ] has closed above bottom band by 23.1%. Bollinger Bands are 0.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.58 - 0.59 0.59 - 0.59
Low: 0.54 - 0.55 0.55 - 0.55
Close: 0.55 - 0.56 0.56 - 0.57

Company Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Headline News

Wed, 16 Nov 2022
Soligenix, Inc. to Showcase 2022 Milestones in Business Update Fireside Chat With PCG Advisory - Yahoo Finance

Mon, 14 Nov 2022
SNGX: HyBryte™ NDA to be Submitted Before the End of 2022… - Yahoo Finance

Sat, 12 Nov 2022
2022-11-11 | NDAQ:SNGX | Press Release | Soligenix Inc. - Stockhouse

Thu, 10 Nov 2022
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results -

Mon, 07 Nov 2022
New to The Street Announces Five Corporate Interviews on Episode #404, Airing on the Fox Business Network, Tonight, Monday, November 7, 2022, at 10:30 PM PT - Yahoo Finance

Fri, 28 Oct 2022
SNGX: Invited to Submit BARDA Contract Proposal for Filovirus Vaccines… - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 43 (M)
% Held by Insiders 4.295e+007 (%)
% Held by Institutions 0.3 (%)
Shares Short 361 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.519e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 771.9
Return on Equity (ttm) -39.9
Qtrly Rev. Growth 858500
Gross Profit (p.s.) 4.07
Sales Per Share -96.67
EBITDA (p.s.) 60910.8
Qtrly Earnings Growth -0.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -12 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -2.1
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 329120
Dividend Yield 0%
Dividend Pay Date 2016-10-06
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.